Satoshi Ohta

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

International journal of molecular sciences

The FEBS journal

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Kengo Takeda, Satoshi Ohta, Miu Nagao, Erika Kobayashi, Kenji Tago, Megumi Funakoshi-Tago
FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5. International journal of molecular sciences 25 (7) (2024)
Kengo Takeda, Satoshi Ohta, Miu Nagao, Erika Kobayashi, Kenji Tago, Megumi Funakoshi-Tago
FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5. International journal of molecular sciences 25 (7) (2024)
Kengo Takeda, Satoshi Ohta, Miu Nagao, Erika Kobayashi, Kenji Tago, Megumi Funakoshi-Tago
FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5. International journal of molecular sciences 25 (7) (2024)
Satoshi Ohta, Kenji Tago, Takahiro Kuchimaru, Megumi Funakoshi-Tago, Hisanaga Horie, Chihiro Aoki-Ohmura, Jitsuhiro Matsugi, Ken Yanagisawa
The role of MerTK in promoting cell migration is enhanced by the oncogenic Ras/IL-33 signaling axis. The FEBS journal (2021)
Kenji Tago, Megumi Funakoshi-Tago, Satoshi Ohta, Hirotoshi Kawata, Hiroshi Saitoh, Hisanaga Horie, Chihiro Aoki-Ohmura, Junji Yamauchi, Akira Tanaka, Jitsuhiro Matsugi, Ken Yanagisawa
Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation. Molecular oncology 13 (11) (2019)